{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Refametinib",
  "nciThesaurus": {
    "casRegistry": "923032-37-5",
    "chebiId": "",
    "chemicalFormula": "C19H20F3IN2O5S",
    "definition": "An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.",
    "fdaUniiCode": "JPX07AFM0N",
    "identifier": "C74059",
    "preferredName": "Refametinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C69145"
    ],
    "synonyms": [
      "BAY 869766",
      "BAY86-9766",
      "MEK Inhibitor RDEA119",
      "RDEA119",
      "REFAMETINIB",
      "Refametinib"
    ]
  }
}